27 results on '"West, Michael L."'
Search Results
2. Retrospective review of recent ASA prescribing practices for primary prevention of major adverse cardiovascular events in the Canadian Fabry Disease Initiative cohort
3. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years
4. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy
5. Chest pain subtype prevalence in the British Columbia cohort of the Canadian Fabry Disease Initiative
6. Facilitating intrafamily communication to enable earlier diagnosis of Fabry disease in relatives: Expert opinion
7. Switch from enzyme replacement therapy to pharmacologic chaperone: Improvement in advanced Fabry nephropathy
8. The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD)
9. FollowME Fabry Pathfinders registry: Renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years
10. Clinical characteristics of female patients enrolled in the FollowME Fabry Pathfinders registry
11. Corrigendum to “Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing” [2021 Sep-Oct;134(1–2):117–131]
12. Long-term outcomes in patients with Fabry disease who were treated with agalsidase alfa for more than nineteen years: The Fabry Outcome Survey
13. Early therapy in Fabry disease: Outcomes from the Canadian Fabry Disease Initiative (CFDI) registry
14. Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: A Fabry Outcome Survey (FOS) analysis
15. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
16. Canadian Fabry disease registry study group: Report on the A143P Nova Scotia genotype
17. Lyso Gb3 and Gb3 analogues in Fabry disease patients with A143P genotype: A cross-sectional analysis by the CFDR study group
18. Routes to diagnosis of Fabry disease according to patient age and geographic distribution
19. Valvular heart disease complicating advanced Fabry disease: Association with chronic kidney disease
20. FACTs Fabry gene therapy clinical trial: Two-year data
21. Renal and cardiac outcomes in female patients with Fabry disease treated with agalsidase beta: A Fabry registry analysis of pre- versus post-treatment comparison
22. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study
23. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease
24. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis
25. Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease
26. Gene therapy for Fabry disease patients: The importance of efficient biomarker monitoring
27. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.